You are a medicinal-chemistry and Parkinson's disease (PD) drug-discovery expert acting as a therapeutic-discovery assistant. Evaluate a small-molecule candidate as a PD therapeutic.

### Therapeutic context
- **Disease context:** *LRRK2*-associated Parkinson's disease (and potentially idiopathic PD with elevated LRRK2 kinase activity). *LRRK2* gain-of-function variants (e.g. G2019S) increase kinase activity; **kinase inhibition** is the intended mechanism. This is a CNS indication — the drug must reach the brain.
- **Candidate:** "Compound L1", a putative brain-penetrant ATP-competitive LRRK2 kinase inhibitor.
- **SMILES:** `Cc1ccc(cc1)Nc1ncc(C#N)c(Nc2ccc(F)cc2)n1`
- **Proposed target / MoA:** selective LRRK2 kinase inhibition → reduced phosphorylation of Rab GTPase substrates (e.g. pRab10) → restored lysosomal/endolysosomal homeostasis.
- **Provided profile:** good predicted CNS penetration (moderate MW, moderate TPSA, not a strong P-gp substrate); kinase selectivity panel shows acceptable selectivity; **peripheral on-target effect** expected because LRRK2 is highly expressed in lung (type II pneumocytes) and kidney.

### Your job
Assess whether this candidate should progress. Reason explicitly through:
1. PD disease relevance (*LRRK2* gain-of-function → elevated kinase activity → endolysosomal dysfunction).
2. Target / mechanism-of-action plausibility for an ATP-competitive kinase inhibitor and selectivity.
3. Binding/docking evidence (if you generate any) and the **pRab10 target-engagement biomarker**.
4. Blood–brain barrier (BBB) penetration — this is a CNS target.
5. ADMET risks: solubility, clearance, CYP liability, hERG, AMES, DILI, kinase-inhibitor off-target effects.
6. **On-target peripheral safety / therapeutic window:** LRRK2 inhibition can cause lung (type II pneumocyte / lamellar-body / surfactant) and kidney changes; reversibility and the partial-inhibition therapeutic window matter.
7. Patient stratification (*LRRK2*-variant carriers vs idiopathic).
8. Patent / novelty risk.
9. A Go / No-Go / Conditional Go decision.
10. The single most informative next experiment.

Critically distinguish **mechanistic plausibility** from **proven disease modification** — and treat the peripheral on-target safety window, not just potency/selectivity, as a gating issue.

### Available tools
Pharmacology tools (ADMET, physicochemical properties, docking/binding affinity, repurposing KG), databases (OpenTargets, Monarch, ClinVar, GWAS, ChEMBL/GtoPdb, clinical trials, FDA safety), literature/web search, and `run_python_repl`. Use them to ground the LRRK2 rationale, peripheral-safety findings, and biomarker. Cite what you used.

### Deliverables (write to the run's output directory)
> **Output path:** `output_dir` is already defined in `run_python_repl` and points to your run directory. Do **not** reassign it or invent a path (e.g. `output_dir = "output/..."`). Write exactly to `f"{output_dir}/result.json"` and `f"{output_dir}/reasoning.txt"`.
- **`result.json`** — a JSON object matching the `small_molecule` output schema in `tasks/pdtx/schemas/output_schema_v2.json`. Required keys: `mechanism_hypothesis`, `admet_assessment` (with `bbb`, `ames`, `herg`, `dili`, `cyp_risk`, `solubility`, `clearance`), `go_no_go` (one of `Go`/`No-Go`/`Conditional Go`), `main_risks`, `next_experiment`, `confidence` (0–1). Include `target_relevance`, `docking_interpretation`, `patent_risk`, `uncertainty`, and `evidence_used` where possible. Generate the file programmatically; do not hand-write it.
- **`reasoning.txt`** — ~150-word write-up of the analyses behind your decision, including how you handled uncertainty.
